NuPathe is a specialty pharmaceutical company focused on innovative neuroscience solutions.
Business Model:
Revenue: $95M
Employees: 201-500
NuPathe was acquired by
Teva Pharmaceutical Industries.
The acquisition happend on 2014-01-21.
Details of the transaction were not public
Address: 7 Great Valley Pkwy
City: Malvern
State: PA
Zip: 19355
Country: US
NuPathe is a specialty pharmaceutical company focused on innovative neuroscience solutions.
Contact Phone:
+16102320800
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
8/6/2010
Ticker Symbol:
PATH
IPO Price:
$10/share
Amount Raised:
$50M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 9/2006 | Series A | 4 | $15M |
Safeguard Scientifics BioAdvance Birchmere Ventures Bay City Capital Safeguard Scientifics BioAdvance Birchmere Ventures |
4/2010 | Debt Financing | 1 | $10.1M |
Birchmere Ventures Birchmere Ventures |
7/2008 | Series B | 7 | $30M |
Bay City Capital Birchmere Ventures SR One Quaker BioVentures Battelle Ventures BioAdvance Safeguard Scientifics Quaker BioVentures SR One Bay City Capital Birchmere Ventures SR One Quaker BioVentures Battelle Ventures BioAdvance Safeguard Scientifics Quaker BioVentures SR One |
10/2012 | Post-IPO Equity | $28M | 11/2012 | Post-IPO Debt | 1 | $8.5M |
Hercules Capital Hercules Capital |
8/2010 | IPO | $50M |
|
10/2005 | Seed Round | 1 | - |
BioAdvance BioAdvance |
6/2011 | Post-IPO Debt | $10M | 10/2005 | Seed Round | 1 | - |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|